China 
Africa 
Explore chapters and articles related to this topic
Differences in C-Reactive Protein (CRP) between depression levels in ischaemic stroke patients
Published in Cut Adeya Adella, Stem Cell Oncology, 2018
S.N. Lubis, W.H. Lubis, I. Nasution
Post-Stroke Depression (PSD) is one of the most common stroke complications, characterised by mood abnormalities, self-blame, and sadness; it is diagnosed in 40-72% of stroke patients. PSD is a major factor that can inhibit the healing function of neurologic stroke patients and increase mortality. Depression will affect patient behaviours, such as medical rehabilitation, smoking, diet, medication adherence, and physical activity. Depression also affects physiological factors such as autonomic nervous system disorders and inflammation (Solnek & Seiter, 2002; Schuyler, 2000).
The Flow brain stimulation headset for the treatment of depression: overview of its safety, efficacy and portable design
Published in Expert Review of Medical Devices, 2020
Lucas Borrione, Paulo J C Suen, Lais B Razza, Leonardo Afonso Dos Santos, Pedro Sudbrack-Oliveira, André R Brunoni
Subsequent studies, involving the use of tDCS in the treatment of unipolar [33–38], bipolar [39], and post-stroke depression [40] displayed mixed results, probably due to diverse stimulation parameters and enrollment of patients with diverse degrees of treatment-resistance [15]. Therefore, to better estimate tDCS effect size in depression, a recent meta-analysis assessed 25 datasets (from 23 RCTs, n = 1092), with tDCS as monotherapy, an add-on or augmentative strategy, in unipolar, bipolar and post-stroke depressive episodes [41]. The authors observed that active tDCS was clinically and moderately superior, and as tolerable as sham, both in continuous (g = 0.46, 95% confidence interval [CI]: 0.22–0.70) and categorical outcomes (response: 33.3% vs. 16.56%, odds ratio = 2.28 [1.52–3.42], number needed to treat = 6; remission: 19.12% vs. 9.78%, OR = 2.12 [1.42–3.16], NNT = 10.7) [41]. These observations are in line with previous meta-analysis, which have demonstrated tDCS superiority over placebo [42,43].